Nyt fra tidsskrifterne
Søgeord (mpox) valgt.
13 emner vises.
BMC Infectious Diseases, 17.10.2024
Tilføjet 17.10.2024
Abstract Introduction During the mpox outbreak in 2022, the highest number of cases in Germany were registered in Berlin, almost all of them in men who have sex with men (MSM). However, the frequency of clinically undiagnosed infections is unknown. Methods A cross-sectional study was conducted among MSM in Berlin, Germany. Participants were recruited from private practices and community-based checkpoints specialised in HIV and STI care for MSM. They were asked to complete an online questionnaire on socio-demographic data, mpox diagnosis, vaccination history and sexual behaviour, and to provide a blood sample for serological analysis. The samples were tested for antibodies against a range of antigens to distinguish between antibodies induced by mpox infection and MVA vaccination, with pre-immune sera from childhood smallpox vaccination as a confounding factor. Associations of behavioural variables with reported and suspected mpox diagnosis as the outcome were tested using univariable and multivariable logistic regression models. Results Between the 11th April and 1st July 2023, 1,119 participants were recruited in eight private practices and two community-based checkpoints in Berlin. All participants provided a blood sample for serological testing. Information for the online questionnaire was provided by 728 participants; core data on age and mpox history for participants who did not provide questionnaire data were provided by the practices for an additional 218 participants. A previous diagnosis of mpox was reported for/by 70 participants (7.4%). Using a conservative and strict case definition, we serologically identified an additional 91 individuals with suspected undiagnosed mpox infection. Individuals with reported or suspected mpox infections reported more condomless anal sex partners in the past 3 months (OR = 5.93; 95% CI 2.10-18.35 for 5–10 partners; OR = 9.53; 95% CI 2.72–37.54 for > 10 partners) and were more likely to report sexual contact with partners diagnosed with mpox (OR = 2.87; 95% CI 1.39–5.84). Conclusion A substantial proportion of mpox infections were clinically undiagnosed. The number of condomless anal sex partners was strongly associated with both confirmed and suspected undiagnosed mpox infection. Therefore, mpox control measures based on clinical diagnosis of mpox are likely to have limited effectiveness in preventing mpox transmission in outbreak situations because many infections remain unrecognised and undiagnosed.
Læs mere Tjek på PubMedJournal of the American Medical Association, 15.10.2024
Tilføjet 15.10.2024
As the mpox virus continues to spread in Africa, the World Health Organization (WHO) has launched a global emergency response plan to limit transmission. As of June 2024, the agency reported, the outbreak has resulted in nearly 100 000 confirmed cases and 200 deaths, mostly in the Democratic Republic of Congo, but also in such neighboring countries as Burundi and Kenya. Both Sweden and Thailand have reported a single travel-related case each.
Læs mere Tjek på PubMedJaime David Acosta-España, Ángeles Costta, Jenny Belén Altamirano-Jara, Andrés Herrera-Yela, D. Katterine Bonilla-Aldana, Alfonso J. Rodriguez-Morales.
Clinical Microbiology and Infection, 15.10.2024
Tilføjet 15.10.2024
On August 14, 2024, WHO\'s Director-General, Dr. Tedros Adhanom Ghebreyesus, declared Mpox a Public Health Emergency of International Concern (PHEIC). This declaration followed a surge in Mpox cases, particularly those caused by clade Ib of the virus, in the Democratic Republic of the Congo and neighbouring African countries [1]. While the global spotlight has primarily focused on adult populations, especially men who have sex with men (MSM), The paediatric risk from Mpox remains significantly underrecognised.
Læs mere Tjek på PubMedBMC Infectious Diseases, 14.10.2024
Tilføjet 14.10.2024
Abstract Introduction During the mpox outbreak in 2022, the highest number of cases in Germany were registered in Berlin, almost all of them in men who have sex with men (MSM). However, the frequency of clinically undiagnosed infections is unknown. Methods A cross-sectional study was conducted among MSM in Berlin, Germany. Participants were recruited from private practices and community-based checkpoints specialised in HIV and STI care for MSM. They were asked to complete an online questionnaire on socio-demographic data, mpox diagnosis, vaccination history and sexual behaviour, and to provide a blood sample for serological analysis. The samples were tested for antibodies against a range of antigens to distinguish between antibodies induced by mpox infection and MVA vaccination, with pre-immune sera from childhood smallpox vaccination as a confounding factor. Associations of behavioural variables with reported and suspected mpox diagnosis as the outcome were tested using univariable and multivariable logistic regression models. Results Between the 11th April and 1st July 2023, 1,119 participants were recruited in eight private practices and two community-based checkpoints in Berlin. All participants provided a blood sample for serological testing. Information for the online questionnaire was provided by 728 participants; core data on age and mpox history for participants who did not provide questionnaire data were provided by the practices for an additional 218 participants. A previous diagnosis of mpox was reported for/by 70 participants (7.4%). Using a conservative and strict case definition, we serologically identified an additional 91 individuals with suspected undiagnosed mpox infection. Individuals with reported or suspected mpox infections reported more condomless anal sex partners in the past 3 months (OR = 5.93; 95% CI 2.10-18.35 for 5–10 partners; OR = 9.53; 95% CI 2.72–37.54 for > 10 partners) and were more likely to report sexual contact with partners diagnosed with mpox (OR = 2.87; 95% CI 1.39–5.84). Conclusion A substantial proportion of mpox infections were clinically undiagnosed. The number of condomless anal sex partners was strongly associated with both confirmed and suspected undiagnosed mpox infection. Therefore, mpox control measures based on clinical diagnosis of mpox are likely to have limited effectiveness in preventing mpox transmission in outbreak situations because many infections remain unrecognised and undiagnosed.
Læs mere Tjek på PubMedRita Cordeiro Constantino P. Caetano Daniel Sobral Rita Ferreira Luís Coelho Ana Pelerito Isabel Lopes de Carvalho Sónia Namorado Dinis B. Loyens Ricardo Mexia Cândida Fernandes José Miguel Neves Ana Luísa João Miguel Rocha Luís Miguel Duque Inês Correia Teresa Baptista Cláudia Brazão Diogo Sousa Paulo Filipe Miguel Alpalhão Fernando Maltez Diana Póvoas Raquel Pinto João Caria Rita Patrocínio de Jesus Patrícia Pacheco Francesca Peruzzu Josefina Méndez Luís Ferreira Kamal Mansinho João Vaz Alves Joana Vasconcelos João Domingos Sara Casanova Frederico Duarte Maria João Gonçalves Mafalda Brito Salvador Mafalda Andresen Guimarães Sueila Martins Marvin Silva Oliveira Daniela Santos Luís Vieira Maria Sofia Núncio Vítor Borges João Paulo Gomes a Emergency Response and Biopreparedness Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugalb Institute of Environmental Health, Faculty of Medicine, University of Lisbon, Lisbon, Portugalc Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugald Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugale Serviço de Dermatovenereologia, Consulta de DST, Unidade Local de Saúde de São José, Lisbon, Portugalf GAT - Grupo de Ativistas em Tratamentos, GAT-CheckpointLX, Lisbon, Portugalg Serviço de Infeccologia, Hospital Garcia de Orta, Almada, Portugalh GAT - Grupo de Ativistas em Tratamentos, GAT-Intendente, Lisbon, Portugali Dermatology Department, Unidade Local de Saúde de Santa Maria, Lisbon, Portugalj Dermatology Research Unit (PFilipe Lab), Instituto de Medicina Molecular João Lobo Antunes, University of Lisbon, Lisbon, Portugalk Dermatology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugall Serviço de Doenças Infeciosas, Hospital de Curry Cabral, Unidade Local de Saúde de São José, Lisbon, Portugalm Instituto Gulbenkian de Ciência, Oeiras, Portugaln Serviço de Infeciologia, Hospital Professor Doutor Fernando Fonseca, Unidade Local de Saúde Amadora/Sintra, Amadora, Portugalo Serviço de Doenças Infecciosas, Centro Hospitalar Universitário de Santo António, Porto, Portugalp Serviço de Doenças Infecciosas e Medicina Tropical, Hospital de Egas Moniz, Unidade Local de Saúde de Lisboa Ocidental, Lisbon, Portugalq Serviço de Doenças Infeciosas, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugalr Unidade de Doenças Sexualmente Transmissíveis, Unidade de Cuidados de Saúde Personalizados da Lapa, Unidade Local de Saúde de São José, Lisbon, Portugals PPCIRA, Unidade de Tratamento de Imunodeficiência, Hospital de Cascais, Lisboa, Portugalt UL-PPCIRA, Unidade Local de Saúde Trás-os-Montes e Alto Douro, Vila Real, Portugalu Serviço de Patologia Clínica, Unidade Local de Saúde do Tâmega e Sousa, Penafiel, Portugalv Technology and Innovation Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugalw Veterinary and Animal Research Centre (CECAV), Faculty of Veterinary Medicine, Lusófona University, Lisbon, Portugal
Emerg Microbes Infect, 12.10.2024
Tilføjet 12.10.2024
Clinical Infectious Diseases, 8.10.2024
Tilføjet 8.10.2024
Abstract Introduction Since its global reemergence in 2022, monkeypox (mpox) has demonstrated increased incidence and severity among people with human immunodeficiency virus (HIV [PWH]). Predictors of mpox diagnosis, vaccination, and outcomes among PWH are limited.Methods We included PWH with primary care visits after 1 January 2022 at 9 US sites participating in the Centers for AIDS Research Network of Integrated Clinic Systems Network. We identified mpox diagnosed between 1 June 2022 and 31 May 2023, through a combination of polymerase chain reaction result, diagnosis code, and/or tecovirimat receipt. We examined validated clinical diagnoses, laboratory results, vaccine data, and patient reported outcomes. We evaluated relative risks (RR) of mpox diagnosis, hospitalization, tecovirimat treatment, and vaccine receipt.Findings Among 19 777 PWH in care, 413 mpox cases (all male sex at birth) occurred (2.2 cases/100 person-years). Age
Læs mere Tjek på PubMedPikka Jokelainen, Anne L. Wyllie, Nitin Gupta, Aleksandra Barac, Effrossyni Gkrania-Klotsas, Casandra Bulescu, José Ramón Paño-Pardo, Marta Mora-Rillo, Martin P. Grobusch, F-Xavier Lescure
Clinical Microbiology and Infection, 6.10.2024
Tilføjet 6.10.2024
The current epidemiological situation regarding mpox, a zoonotic viral disease caused by the monkeypox virus (MPXV), is complex. Multiple simultaneous epidemics involving distinct clades of MPXV are occurring across different geographic regions, each affecting distinct at-risk populations. Particularly concerning is the emergence of clade Ib, about which much remains unknown.
Læs mere Tjek på PubMedSusan Pasnick, Charles DeLa, Graham Carlos, Shazia Jamil
American Journal of Respiratory and Critical Care Medicine , 2.10.2024
Tilføjet 2.10.2024
American Journal of Respiratory and Critical Care Medicine, Volume 210, Issue 7, Page P1-P2, October 1, 2024.
Læs mere Tjek på PubMedBMC Infectious Diseases, 1.10.2024
Tilføjet 1.10.2024
Abstract Background Since May 7 2022, mpox has been endemic in many countries which has attracted the attention of health authorities in various countries and made control decisions, in which vaccination is the mainstream strategy. However, the shortage of vaccine doses and the reduction of protective efficacy have led to unresolved issues such as vaccine allocation decisions and evaluation of transmission scale. Methods We developed an epidemiological model to describe the prevalence of the mpox virus in New York City and calibrated the model to match surveillance data from May 19 to November 3, 2022. Finally, we adjusted the model to simulate and compare several scenarios of non-vaccination and pre-pandemic vaccination. Results Relative to the status quo, if vaccination is not carried out, the number of new infections increases to about 385%, and the transmission time will be extended to about 350%, while if vaccinated before the epidemic, the number of new infections decreases to 94.2-96%. Conclusions The mpox outbreak in New York City may be linked to the Pride event. However, with current vaccine coverage, there will be no more large-scale outbreaks of mpox, even if there is another similar activity. For areas with limited vaccines, priority is given to high-risk groups in the age group [34–45] years as soon as possible.
Læs mere Tjek på PubMedPaul Adepoju
Lancet, 27.09.2024
Tilføjet 27.09.2024
More than a million doses have also been promised to African countries in the coming year. Paul Adepoju reports.
Læs mere Tjek på PubMedMateo Prochazka, Pietro Vinti, Ana Hoxha, Andy Seale, Antons Mozalevskis, Rosamund Lewis, Ruben Mayorga Sagastume, Martha Scherzer, Leilia Dore, Meg Doherty
Lancet Infectious Diseases, 19.09.2024
Tilføjet 19.09.2024
Adaptations to sexual behaviour due to mpox were widespread, dynamic, and responded to evolving individual risk perceptions. We propose that the decline in mpox transmission seen at the end of 2022 resulted primarily from a combination of behavioural adaptation and naturally acquired immunity. As mpox vaccination is an important preventive measure, stark vaccine inequity highlights the need to increase access to mpox vaccines.
Læs mere Tjek på PubMedZuning Ren Mengjun Li Jiayin Chen Xiaohua Gong Shuo Song Delin Li Minghui Yang Jianhai Yu Sadia Asghar Yanxin Cui Shiyu Niu Zhonghui Liao Yushan Jiang Jiahui Liu Yuqing Li Bao Zhang Wei Zhao Jie Peng Yang Yang Chenguang Shen a State Key Laboratory of Organ Failure Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of Chinab BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, People’s Republic of Chinac Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, People’s Republic of Chinad Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, People’s Republic of Chinae School of Life Science, Advanced Research Institute of Multidisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People’s Republic of Chinaf Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistang Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Ministry of Education, People’s Republic of China
Emerg Microbes Infect, 19.09.2024
Tilføjet 19.09.2024
BMC Infectious Diseases, 18.09.2024
Tilføjet 18.09.2024
Abstract Background Mpox is a severe viral zoonosis that has emerged as a public health concern due to its potential for human-to-human transmission and severe illness. Understanding its clinical manifestations is crucial for effective management and control. Several systematic reviews have assessed various manifestations of Mpox. This umbrella review synthesizes evidence on Mpox’s manifestations across different organ systems. Method We conducted an umbrella review, adhering to Joanna Briggs Institute (JBI) methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on systematic reviews of Mpox manifestations. We performed a literature search up to 25th September 2023, in databases like PubMed, Embase, and Web of Science. We included systematic reviews of observational studies, case reports, case series, or RCTs reporting any manifestations of Mpox in humans, focusing on a global scope. AMSTAR 2 was used to evaluate the quality of systematic reviews, and data has been synthesized in narrative and tabular manners. Results A total of 25 systematic reviews were included, uncovering diverse manifestations of Mpox, such as cutaneous, cardiovascular, oral, ophthalmic, gastrointestinal, respiratory, and pregnancy-related. Cutaneous manifestations (up to 100%) were the most prevalent, featuring lesions and rashes. Constitutional symptoms of viral illness were reported in ~ 60% to > 85% of the cases. Significant respiratory symptoms were present in ~ 50% of cases overall. Headaches were the leading neurological symptom present in > 30%. Symptoms of gastrointestinal involvement ranged from 39% (oral lesions) with decreasing frequency to low diarrhea at ~ 5%, with proctitis percentages ranging from high teens to mid-twenties. Ophthalmic manifestations (6% but with wide variations among studies). Many primary studies included in the systematic reviews consisted of case reports and case series. A wide range of manifestations across different organ systems was observed. Negative outcomes for pregnancies were reported, but evidence is limited. Adverse cardiovascular and neurological outcomes were identified, though only a few studies provided insights into these findings. Conclusion Mpox exhibits diverse manifestations, impacting multiple organ systems, with substantial variations. The findings highlight the importance of ongoing, nuanced, and region-specific research and management strategies for Mpox. The reliance on case reports and series underscores the need for more high-quality, long-term studies to deepen our understanding and management of this significant public health concern.
Læs mere Tjek på PubMed